Hepion Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $1.65M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Hepion Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Hepion Pharmaceuticals filed with the SEC
Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
Material agreement · Other events · EX-99.1 to Form 8-K
Short-term portion of contingent consideration
Other events · EX-99.1 to Form 8-K/A
Consolidated Balance Sheet as of January 31, 2025
Other events · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
Agreement terminated · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Executive or director change · Other events · EX-99.1 to Form 8-K
Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
1 1 Rencofilstat (CRV431): A Novel Drug Candidate for NASH, Fibrosis, and HCC July 2023 Creating a Therapeutic Ecosystem NASDAQ: HEPA
Regulation FD disclosure · EX-99.1 to Form 8-K
A Novel Drug Candidate for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Pharmaceuticals, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
1 1 Rencofilstat (CRV431): A Novel Drug Candidate for NASH, Fibrosis, and HCC October 2022 Creating a Therapeutic Ecosystem NASDAQ: HEPA
Regulation FD disclosure · EX-99.1 to Form 8-K
A liver-targeting drug candidate for
Regulation FD disclosure · EX-99.1 to Form 8-K
Upcoming Phase 2 Clinical Trials of Recofilstat at 5 th Global NASH Congress
Regulation FD disclosure · EX-99.2 to Form 8-K
1 1 Rencofilstat (CRV431): A liver - targeting drug candidate for NASH and HCC January 2022 | INVESTOR PRESENTATION smart drug smart technology smart development
Regulation FD disclosure · EX-99.1 to Form 8-K
USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
Other events · EX-99.1 to Form 8-K
FDA Clearance of IND Application for CRV431 in the
Other events · EX-99.1 to Form 8-K
FDA Fast Track Designation for CRV431 for the Treatment of NASH
Other events · EX-99.1 to Form 8-K
Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
Other events · EX-99.1 to Form 8-K
Poster Details for the Upcoming AASLD The Liver
Other events · EX-99.1 to Form 8-K
Pharmaceuticals’ CRV431 Highlighted in Scripps Research
Other events · EX-99.2 to Form 8-K
in the H.C. Wainwright 5th Annual NASH Investor Conference
Other events · EX-99.1 to Form 8-K